12/16
10:25 pm
rvph
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
High
Report
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
12/16
05:18 pm
rvph
Reviva Announces Proposed Public Offering
High
Report
Reviva Announces Proposed Public Offering
12/16
08:07 am
rvph
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]
High
Report
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]
12/16
08:00 am
rvph
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
High
Report
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
11/14
05:32 pm
rvph
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
05:25 pm
rvph
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/12
08:00 am
rvph
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
High
Report
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
11/6
08:00 am
rvph
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
Low
Report
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
10/31
08:00 am
rvph
Reviva to Participate in the UBS Global Healthcare Conference
Neutral
Report
Reviva to Participate in the UBS Global Healthcare Conference
10/8
08:00 am
rvph
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
Medium
Report
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
10/2
08:30 am
rvph
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Medium
Report
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
9/26
08:30 am
rvph
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
Medium
Report
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
9/25
07:40 am
rvph
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Medium
Report
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.